Veteran banker Jessica Chutter joins Tectonic (NASDAQ: TECX) board
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Tectonic Therapeutic, Inc. appointed Jessica Chutter to its Board of Directors and Audit Committee, effective as of the company’s 2026 annual stockholder meeting, described in the press release as June 8, 2026. She will serve as a Class III director with a term expiring at the 2027 annual meeting and has been determined to be an independent director under Nasdaq rules.
As a non-employee director, Ms. Chutter is eligible for an annual cash retainer of $40,000 for Board service and $7,500 for Audit Committee service, plus a one-time option grant for 20,400 shares under the 2024 Equity Incentive Plan. The initial option vests over three years, and future annual option grants are expected after each stockholder meeting, with vesting tied to continued Board service and accelerated vesting upon a qualifying change in control.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 5.02, 7.01, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Board service retainer: $40,000 per year
Audit Committee retainer: $7,500 per year
Initial option grant: 20,400 shares
+5 more
8 metrics
Board service retainer
$40,000 per year
Annual cash retainer for Board service under non-employee director policy
Audit Committee retainer
$7,500 per year
Additional annual cash retainer for Audit Committee service
Initial option grant
20,400 shares
One-time stock option award under 2024 Equity Incentive Plan
Initial vesting cliff
1 year
One-third of initial option vests on first anniversary of grant
Full vesting period
3 years
Remaining initial option vests in monthly installments to third anniversary
Effective date
June 8, 2026
Appointment effective as of 2026 annual stockholder meeting
Class III term end
2027 annual meeting
Director term scheduled to expire at 2027 annual stockholder meeting
Capital transactions advised
$80 billion
Approximate capital raising transactions Ms. Chutter advised in her career
Key Terms
independent director, Audit Committee, non-employee director compensation policy, change in control, +2 more
6 terms
independent director regulatory
"The Board has determined that Ms. Chutter qualifies as an “independent director”"
An independent director is a member of a company's board of directors who is not involved in the company's day-to-day operations and has no significant relationships with the company that could influence their judgment. Their role is to provide unbiased oversight and ensure the company is managed in the best interests of all shareholders. This helps build trust and confidence among investors by promoting transparency and accountability.
Audit Committee regulatory
"appointed Jessica Chutter as a member of the Board and as a member of the Audit Committee"
A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.
non-employee director compensation policy financial
"Ms. Chutter will be eligible, as of the Effective Date, to participate in the Company’s non-employee director compensation policy"
change in control financial
"immediately prior to a “change in control” as defined under the 2024 Plan, all of Ms. Chutter’s then-outstanding equity awards"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
clinical-stage biotechnology company financial
"a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies"
forward-looking statements regulatory
"This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
FAQ
What did Tectonic Therapeutic (TECX) announce on April 23, 2026?
Tectonic Therapeutic appointed Jessica Chutter to its Board of Directors and Audit Committee, effective at the 2026 annual stockholder meeting, with her term as a Class III director running until the 2027 annual stockholder meeting.
What compensation will Jessica Chutter receive as a Tectonic Therapeutic (TECX) director?
As a non-employee director, Jessica Chutter is eligible for a $40,000 annual Board retainer, an additional $7,500 for Audit Committee service, and a one-time stock option grant for 20,400 shares under the 2024 Equity Incentive Plan, subject to vesting.
When does Jessica Chutter’s board appointment at Tectonic Therapeutic (TECX) become effective?
Her appointment is effective as of the date of Tectonic’s 2026 annual stockholder meeting, described in the press release as June 8, 2026, and she will serve until a successor is appointed or she departs earlier.
Is Jessica Chutter considered an independent director at Tectonic Therapeutic (TECX)?
Yes. Tectonic’s Board determined that Jessica Chutter qualifies as an independent director under Nasdaq Rule 5605(a)(2), meaning she meets the exchange’s standards for independence from the company’s management and related parties.
How do Jessica Chutter’s stock options at Tectonic Therapeutic (TECX) vest?
Her initial option for 20,400 shares vests one-third on the first anniversary of grant, with the remainder vesting in equal monthly installments until the third anniversary, and all such awards fully vest if she serves until just before a qualifying change in control.
What is Tectonic Therapeutic’s (TECX) business focus?
Tectonic Therapeutic is a clinical-stage biotechnology company developing therapeutic proteins and antibodies that modulate G-protein coupled receptors using its GEODe platform, targeting diseases with significant unmet medical need and limited or poor existing treatment options.